Mannkind (MNKD) Cash from Operations Growth (1y) (2011 - 2026)

Mannkind (MNKD) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 7.14%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 356.73%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 74.39%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 3.23%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Mannkind 1.20 Bn 1.07 Bn 82.66 Mn 15.87%

Historic Data

Download Data
DateValue
Mar 31, 2026 15.87%
Dec 31, 2025 -135.14%
Sep 30, 2025 153.35%
Jun 30, 2025 133.50%
Mar 31, 2025 -195.14%
Dec 31, 2024 4.46%
Sep 30, 2024 7.70%
Jun 30, 2024 47.65%
Mar 31, 2024 479.84%
Dec 31, 2023 1,012.37%
Sep 30, 2023 130.86%
Jun 30, 2023 108.12%
Mar 31, 2023 106.33%
Dec 31, 2022 80.76%
Sep 30, 2022 -84.89%
Jun 30, 2022 -49.12%
Mar 31, 2022 -43.34%
Dec 31, 2021 -5,354.04%
Sep 30, 2021 -12.81%
Jun 30, 2021 -482.17%